相关实验视频
Updated: Jan 13, 2026

10:30
Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
Published on: January 25, 2017
9.3K
通过PGE-2-IL-22轴,由乙氨基基基衍生出的COX-2可以防止实验性结肠炎
Yang Yang1, Constance L Atkins1, Yuanyuan Fan1
1Department of Anesthesiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
bioRxiv : the preprint server for biology
|January 7, 2026
概括
埃索诺菲尔使用循环氧化酶-2 (COX-2) 产生前列腺素E2 (PGE2),从而增强IL-22.2. 这条通路在炎症性肠病 (IBD) 模型中保护肠道屏障,提供了一个新的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 炎症性肠病 (IBD) 涉及免疫失调和上皮屏障缺陷.
- 在IBD病变发生过程中,乙酸蛋白的作用尚不清楚.
- 在IBD中,乙氨基酸透到肠道粘膜中,但它们对疾病结果的具体贡献仍然存在争议.
研究的目的:
- 为了研究乙酸蛋白在IBD病变发生过程中的作用.
- 为了识别由eosinophils影响肠道炎症的分子机制.
- 探索IBD中以埃索诺菲尔为媒介的途径中的潜在治疗点.
主要方法:
- 从用硫酸 (DSS) 治疗的小鼠中对结肠埃索诺菲尔的RNA测序.
- 产生和分析埃索诺菲尔特异性循环氧化酶-2 (COX-2) 的淘汰赛小鼠 (Ptgs2fl/fleoCre+/-).
- 使用DSS和三二硫酸 (TNBS) 模型诱导大肠炎.
- 评估疾病严重程度,结肠组织学和细胞因子的产生 (IL-22).
- 对前列腺素E2 (PGE2) 信号通路的研究.
主要成果:
- 接受DSS治疗的小鼠的结肠氨基酸显示出高调的COX-2 (基因名称,Ptgs2).
- 埃索诺菲尔特异性去除COX-2加剧了DSS和TNBS诱导的大肠炎,增加了体重减轻,疾病活性和上皮损伤.
- 消去eosinophils中的COX-2降低了3型先天性淋巴细胞 (ILC3) 的IL-22产生.
- 再组合IL-22或PGE2模拟剂的使用恢复了粘膜保护和改善了结肠炎表型.
- 在缺乏乙素COX-2的小鼠中观察到结肠PGE2水平降低.
结论:
- 氨基酸衍生的COX-2和PGE2是结肠炎期间IL-22产生的关键调节剂.
- 由COX-2/PGE2介导的,以前未被识别的乙酸和ILC3之间的交叉声,保护了肠道屏障.
- 这种埃索诺菲尔-ILC3轴代表了IBD的有前途的治疗标.
相关概念视频
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
Drugs for Treatment of Ulcerative Colitis in IBD
449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
1.1K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.1K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K

